SEARCH

SEARCH BY CITATION

References

  • Ahn S., Cheng C., Phillips A. G. and Lee C. S. (2004) Reversal of the dopamine transporter in the severely 6-OHDA lesioned striatum with chronic l-DOPA treatment: a Reverse Dialysis Study with GBR 12909. Soc. Neurosci. Abstr. View. 562.3.
  • Andersson M., Hilbertson A. and Cenci M. A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461474.
  • Aubert I., Guigoni C., Hakansson K. et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57, 1726.
  • Cenci M. A. (2002) Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23, 105109.
  • Cenci M. A., Lee C. S. and Bjorklund A. (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 26942706.
  • Cenci M. A., Whishaw I. Q. and Schallert T. (2002) Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574579.
  • Chase T. N. (1998) Levodopa therapy: consequences of the non-physiologic replacement of dopamine. Neurology 50, S17S25.
  • Contin M., Riva R., Martinelli P., Cortelli P., Albani F. and Baruzzi A. (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43, 367371.
  • Fahn S. (2000) The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47, S2S11.
  • De La Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J. Q., Calne D. B., Ruth T. J. and Stoessl A. J. (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127, 27472754.
  • Horne M. K., Cheng C. H. and Wooten G. F. (1984) The cerebral metabolism of 1-dihydroxyphenylalanine. An autoradiographic and biochemical study. Pharmacology 28, 1226.
  • Igarashi K., Hotta K., Kasuya F., Abe K. and Sakoda S. (2003) Determination of cabergoline and l-dopa in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 792, 5561.
  • Jacobs B. L. and Azmitia E. C. (1992) Structure and function of the brain serotonin system. Physiol. Rev. 72, 165229.
  • Lopez A., Munoz A., Guerra M. J. and Labandeira-Garcia J. L. (2001) Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103, 639651.
  • Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci M. A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120132.
  • Luquin M. R., Scipioni O., Vaamonde J., Gershanik O. and Obeso J. A. (1992) Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7, 117124.
  • Marsden C. D., Parkes J. D. and Quinn N. (1981) Fluctuations in disability in Parkinson's disease – clinical aspects, in Movement Disorders (MarsdenC. D. and FahnS., eds), pp.96122. Butterworths, London.
  • Melamed E., Hefti F., Pettibone D. J., Liebman J. and Wurtman R. J. (1981) Aromatic l-amino acid decarboxylase in rat corpus striatum: implications for action of l-dopa in parkinsonism. Neurology 31, 651655.
  • Nutt J. G. (1992) Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease, in Drug-Induced Movement Disorders (Lang, A. E. and Weiner, W. J., eds), pp.281314. Futura Publishing Co. Inc., Mount Kisko.
  • Obeso J. A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J. L. and Rodriguez-Diaz M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62, S17S30.
  • Olanow C. W., Gauger L. L. and Cedarbaum J. M. (1991) Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann. Neurol. 29, 556559.
  • Papa S. M., Engber T. M., Kask A. M. and Chase T. N. (1994) Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662, 6974.
  • Pardridge W. M. and Oldendorf W. H. (1975) Kinetic analysis of blood–brain barrier transport of amino acids. Biochim. Biophys. Acta 401, 128136.
  • Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M. A. and Calabresi P. (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501506.
  • Rajput A. H., Fenton M. E., Di Paolo T., Sitte H., Pifl C. and Hornykiewicz O. (2004) Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat. Disord. 10, 221226.
  • Schmidt R. H., Björklund A., Stenevi U., Dunnett S. B. and Gage F. H. (1983) Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol. Scand. Suppl. 522, 1937.
  • Wade L. A. and Katzman R. (1975a) Synthetic amino acids and the nature of l-DOPA transport at the blood–brain barrier. J. Neurochem. 25, 837842.
  • Wade L. A. and Katzman R. (1975b) Rat brain regional uptake and decarboxylation of l-DOPA following carotid injection. Am. J. Physiol. 228, 352359.
  • Winkler C., Kirik D., Bjorklund A. and Cenci M. A. (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165186.
  • Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290296.